Cargando…
Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience
PURPOSE: Lung transplantation (LT) is a lifesaving treatment for Covid-19 related lung disease with early outcomes similar to other indications. METHODS: Seven patients underwent LT for Covid-19 related lung disease at our center: 5 for ARDS and 2 for IPF exacerbation post SARS-CoV-2 infection. RESU...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988606/ http://dx.doi.org/10.1016/j.healun.2022.01.1548 |
_version_ | 1784682999375200256 |
---|---|
author | Franco-Palacios, D.J. Allenspach, L. Stagner, L. Pinto-Corrales, J. Hanlon, K. Nappo, T. Sherbin, E. Sternberg, D. Dillon, W. Simanovski, J. Alangaden, G. |
author_facet | Franco-Palacios, D.J. Allenspach, L. Stagner, L. Pinto-Corrales, J. Hanlon, K. Nappo, T. Sherbin, E. Sternberg, D. Dillon, W. Simanovski, J. Alangaden, G. |
author_sort | Franco-Palacios, D.J. |
collection | PubMed |
description | PURPOSE: Lung transplantation (LT) is a lifesaving treatment for Covid-19 related lung disease with early outcomes similar to other indications. METHODS: Seven patients underwent LT for Covid-19 related lung disease at our center: 5 for ARDS and 2 for IPF exacerbation post SARS-CoV-2 infection. RESULTS: Seven patients (5 men) with single organ failure underwent bilateral LT. Median age was 47 years old. All ARDS cases had poor lung mechanics on invasive mechanical ventilation with radiographic evidence of lung fibrosis: pneumatocele, GGO, consolidations, subpleural reticulations and traction bronchiectasis. vvECMO was bridge to transplant in 5 cases (bridge to recovery in 2). Median ECMO duration for ARDS was 32 days (range 7-99). Median time to LT from Covid diagnosis was 59 days (Q1-IQ3, 54-62). Two patients were post-partum women with ARDS. Explanted pathology showed UIP, DAD, diffuse hemorrhage and one case of fibrosing NSIP. Pulmonary hypertension was seen in 4 cases. One patient did not survive. Organizing pneumonia and granuloma were present in this patient. Most ARDS patients were unable to tolerate lower sedation and consent by a substitute decision-makers was obtained. Post operative ECMO decannulation was possible in all cases. Induction, maintenance immunosuppression and antimicrobials were standard for our program. Donated grafts were from deceased brain death donors and negative for 2019-nCoV. Rehabilitation potential and strong social support were absolute inclusion criteria. All survivors have excellent lung function. CONCLUSION: In the USA, over 130 LT have listed Covid-19 as the diagnosis indication. Although Covid-19 ARDS makes up for the majority of these LT, other diagnosis are post Covid pulmonary fibrosis and underlying fibrosis with SARS-CoV-2 induced exacerbation. LT for ARDS poses several challenges and is reserved for the minority of carefully selected patients dependent on extracorporeal life support. As others have reported, good short-term survival is described. |
format | Online Article Text |
id | pubmed-8988606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89886062022-04-11 Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience Franco-Palacios, D.J. Allenspach, L. Stagner, L. Pinto-Corrales, J. Hanlon, K. Nappo, T. Sherbin, E. Sternberg, D. Dillon, W. Simanovski, J. Alangaden, G. J Heart Lung Transplant (969) PURPOSE: Lung transplantation (LT) is a lifesaving treatment for Covid-19 related lung disease with early outcomes similar to other indications. METHODS: Seven patients underwent LT for Covid-19 related lung disease at our center: 5 for ARDS and 2 for IPF exacerbation post SARS-CoV-2 infection. RESULTS: Seven patients (5 men) with single organ failure underwent bilateral LT. Median age was 47 years old. All ARDS cases had poor lung mechanics on invasive mechanical ventilation with radiographic evidence of lung fibrosis: pneumatocele, GGO, consolidations, subpleural reticulations and traction bronchiectasis. vvECMO was bridge to transplant in 5 cases (bridge to recovery in 2). Median ECMO duration for ARDS was 32 days (range 7-99). Median time to LT from Covid diagnosis was 59 days (Q1-IQ3, 54-62). Two patients were post-partum women with ARDS. Explanted pathology showed UIP, DAD, diffuse hemorrhage and one case of fibrosing NSIP. Pulmonary hypertension was seen in 4 cases. One patient did not survive. Organizing pneumonia and granuloma were present in this patient. Most ARDS patients were unable to tolerate lower sedation and consent by a substitute decision-makers was obtained. Post operative ECMO decannulation was possible in all cases. Induction, maintenance immunosuppression and antimicrobials were standard for our program. Donated grafts were from deceased brain death donors and negative for 2019-nCoV. Rehabilitation potential and strong social support were absolute inclusion criteria. All survivors have excellent lung function. CONCLUSION: In the USA, over 130 LT have listed Covid-19 as the diagnosis indication. Although Covid-19 ARDS makes up for the majority of these LT, other diagnosis are post Covid pulmonary fibrosis and underlying fibrosis with SARS-CoV-2 induced exacerbation. LT for ARDS poses several challenges and is reserved for the minority of carefully selected patients dependent on extracorporeal life support. As others have reported, good short-term survival is described. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988606/ http://dx.doi.org/10.1016/j.healun.2022.01.1548 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (969) Franco-Palacios, D.J. Allenspach, L. Stagner, L. Pinto-Corrales, J. Hanlon, K. Nappo, T. Sherbin, E. Sternberg, D. Dillon, W. Simanovski, J. Alangaden, G. Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience |
title | Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience |
title_full | Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience |
title_fullStr | Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience |
title_full_unstemmed | Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience |
title_short | Early Outcomes of Lung Transplantation for COVID-19 Related Lung Disease. Single Center Experience |
title_sort | early outcomes of lung transplantation for covid-19 related lung disease. single center experience |
topic | (969) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988606/ http://dx.doi.org/10.1016/j.healun.2022.01.1548 |
work_keys_str_mv | AT francopalaciosdj earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT allenspachl earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT stagnerl earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT pintocorralesj earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT hanlonk earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT nappot earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT sherbine earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT sternbergd earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT dillonw earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT simanovskij earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience AT alangadeng earlyoutcomesoflungtransplantationforcovid19relatedlungdiseasesinglecenterexperience |